← All Viridian Therapeutics, Inc\de filings

Viridian Therapeutics, Inc\de 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
VRDN
Viridian Therapeutics, Inc\de
10-K: Viridian Therapeutics Secures $300M in Revenue Rights Deal, Advances TED Pipeline
Viridian Therapeutics, Inc. announced a significant revenue participation right sale of up to $300 million and provided updates on its advanced Thyroid Eye Disease (TED) programs, veligrotug and elegrobart, alongside its FcRn and TSHR inhibitor portfolios.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
10-K: Viridian Therapeutics Reports Positive Phase 3 Data, Eyes BLA Submission for TED Treatment
Viridian Therapeutics' 10-K filing highlights positive Phase 3 results for veligrotug in thyroid eye disease (TED) and outlines plans for BLA submission, while also advancing its FcRn inhibitor portfolio.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
10-K: Viridian Therapeutics Outlines Pipeline Progress in Annual 10-K Filing, Eyes 2024 Milestones
Viridian Therapeutics' annual 10-K filing details progress in its pipeline, particularly for thyroid eye disease (TED) treatments and FcRn inhibitors, with key Phase 3 data expected in 2024.